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Abstract 
Objectives: Angiodysplasia is a relatively uncommon cause of GI bleeding in children and may 
be seen in right heart failure. Octreotide has been used successfully in adult patients with 
gastrointestinal bleeding due to angiodysplasias.  
Methods: We describe two patients who had congenital heart disease with right heart failure and 
gastrointestinal bleeding from angiodysplasia. 
Results: Angiodysplasia lesions were documented on traditional endoscopy and capsule 
endoscopy. Bleeding resolved after initiation of IV octreotide and did not recur on subcutaneous 
octreotide during the two year follow up period.  
Conclusions: Based on the successful outcomes in the two patients, a trial of octreotide may be 
considered in pediatric patients who present with gastrointestinal bleeding secondary to 
angiodysplasia. 
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 What is known: 
 
1. Angiodysplasias can cause gastrointestinal bleeding.  
2. Octreotide has been used successfully to help control gastrointestinal bleeding in adult patients 
with variceal bleeding. 
 
What is new: 
 
1. Identification of angiodysplasia as source of significant GI bleeding in children with right 
heart failure.  
2. Utilization of octreotide for control of bleeding from angiodysplasias.  
  
Introduction 
Angiodysplasias (AD) are the most common vascular anomalies of the gastrointestinal tract. 
These are the second most common cause of gastrointestinal bleeding in adults. There is higher 
prevalence of AD in patients with end-stage renal disease, von Willebrand disease (vWD), and 
adults with aortic stenosis (Heyde's syndrome). We describe 2 patients with right heart failure 
who presented with gastrointestinal bleeding due to angiodysplasias which was treated with 
octreotide.  
 
Methods:  
This study was a retrospective review of the electronic medical records of two pediatric patients 
with right failure and gastrointestinal bleeding at Riley Hospital for Children at Indiana 
University Health. The study was approved by the Institutional Review Board (IRB).  
 
Results: 
A 17-year-old female (Patient A) with pulmonary stenosis, tricuspid atresia, hypoplastic right 
ventricle status post Fontan procedure, and protein losing enteropathy presented at age 14 years 
with anemia (Hb 7-8g/dL). Her hemoglobin dropped (from baseline of 16g/dL) to 5.1g/dL. She 
required four units of blood. CT angiogram did not reveal any vascular malformation. She 
underwent upper endoscopy and colonoscopy which revealed vascular ectasias within the second 
part of the duodenum (Figure 1). Capsule endoscopy showed active bleeding attributed to 
angioectasias and small clots throughout the small bowel, especially in the terminal ileum . As 
she continued to bleed, she was started on octreotide with a bolus of 1mcg/kg followed by a 
continuous infusion at the rate of 1mcg/kg/hr for 60 hours and then switched to 50mcg 
subcutaneous injections thrice daily for 14 days. The gastrointestinal bleeding resolved and her 
hemoglobin stabilized (Figure 2). She was then transitioned to octreotide 10 mg monthly depot 
octreotide injections. She did not have any further hematochezia episodes during her treatment 
over a period of 2 years. She later developed asymptomatic vitamin B12 deficiency. The 
medication was discontinued uneventfully after 2 years with stable hemoglobin.  
 
A 14-year-old male (Patient B) with hypoplastic left heart syndrome status post Fontan and 
Norwood procedures, portal hypertension, cirrhosis and ascites developed bloody stools and a 
drop in hemoglobin to 8.7g/dL. He underwent an emergent endoscopy with flexible 
sigmoidoscopy. No abnormalities were found. A Meckel's scan was negative. Capsule 
endoscopy showed blood in the ileocecal region although no discrete lesions were noted.  He 
underwent colonoscopy which showed erythema in cecum and terminal ileum. Biopsies 
demonstrated dilated blood vessels filled with red blood cells, consistent with vascular ectasias 
(Figure 3). He received a bolus of 1mcg/kg of octreotide followed by 1mcg/kg/hr continuous 
infusion and then 100 mcg subcutaneous injections twice daily. As he continued to have bloody 
stools, the dose of subcutaneous octreotide was increased to 150 mcg three times daily. Bloody 
stools resolved and he was started on long-acting depot octreotide 10 mg monthly injections. His 
hemoglobin stabilized and increased to the baseline (Figure 4). After two years without bleeding, 
octreotide was discontinued. He ultimately underwent heart transplant. Unfortunately, he died 
several years later due to complications of heart disease. 
 
Discussion: 
Gastrointestinal bleeding may be caused by various vascular anomalies like hemangiomas, 
angiodysplasias, gastric antral vascular ectasia (GAVE), radiation induced vascular ectasia and 
Dieulafoy’s lesions. [1] Angiodysplasias (AD) are a common cause of occult as well as overt 
gastrointestinal bleeding in older patients. These may be asymptomatic or present with life-
threatening bleeding. These are, however, a rare cause of gastrointestinal bleeding in children.  
Histologically, AD are defined as abnormal, ectatic, dilated, tortuous and usually small (<10 
mm) blood vessels visualized within the mucosal and submucosal layers of the gastrointestinal 
tract. The affected vessels are lined by endothelium only with little or no smooth muscle. Most 
AD (54–81.9%) are detected in the cecum and ascending colon. [2]  
 
The etiology of AD is not completely understood. These lesions are thought to develop 
secondary to chronic low-grade intermittent obstruction of submucosal veins as in patients with 
heart conditions causing elevated right heart pressures. Increased levels of vascular endothelial 
growth factor leading to dysregulated angiogenesis may also play a role in their development.[2] 
Congenital AD are found in younger patients presenting with gastrointestinal bleeding with no 
underlying medical illness. Acquired AD has a higher association with chronic kidney disease, 
cardiovascular disease (especially aortic valve disease) and vWD. [3, 4] 
 
Endoscopy is currently the mainstay for diagnosis of AD. Esophagogastroduodenoscopy, 
colonoscopy and small bowel enteroscopy are used diagnostically for upper gastrointestinal, 
colonic and small bowel AD, respectively. Wireless capsule endoscopy has emerged as the first 
line investigation for the small bowel lesions as it is safer and has a higher yield compared to 
other invasive procedures. [2] 
 
The treatment of AD includes endoscopic therapy and pharmacologic therapy (somatostatin 
analogues, hormonal therapy and thalidomide). Somatostatin is a peptide secreted by 
gastrointestinal cells. It decreases bleeding via a number of potential mechanisms including 
reduced splanchnic blood flow, increased vascular resistance, inhibition of angiogenesis, 
inhibition of pepsin, gastric acid secretion and increased platelet aggregation.[5] Most of the 
literature published on the use of octreotide in AD is in adult patients. In a retrospective analysis 
of 98 patients with a history of bleeding due to AD, all patients received octreotide 0.1 mg tid for 
28 days and, then long acting octreotide 20 mg monthly, from day 14 for 6 months. There was a 
significant increase in the mean hemoglobin levels and the number of bleeding episodes, 
hospitalizations, patients requiring blood transfusions and units of transfused red cells 
significantly decreased amongst all patients over the two-year period. [6] In another study, 24 
patients with refractory small bowel angiodysplasias were treated with 20 mg of long acting 
octreotide for a minimum of three months. 83% of patients had undergone APC (Argon Plasma 
Coagulation) with DBE (Double balloon enteroscopy) within a week prior to initiating octreotide 
therapy. The response was assessed by rates of rebleeding, hemoglobin levels and transfusion 
requirements. 70 % patients had a complete response and 20% patients had a partial response. 
Average hemoglobin rate increase from 9.19 g/dL to 11.35g/dL. [7]  Long term efficacy of 
octreotide in prevention of rebleeding from AD was evaluated in a placebo controlled trial. 32 
patients with bleeding from AD were treated with octreotide 50 mu 12 h subcutaneously. These 
patients were followed for a period of 2 years. Treatment failure occurred in 23% of patients in 
the octreotide group and 48% in the placebo group. No significant differences between the 
groups were observed according to number of bleeding episodes.[8] A systematic review and 
meta-analysis of 22 clinical trials to examine the efficacy of different modalities for management 
of gastrointestinal angiodysplasia was published in 2014. 72 adult patients (in four studies) out of 
the 831 total patients included in the analysis received octreotide. These patients were refractory 
to endoscopic therapy. The pooled odds ratio was reported to be 14.5 for cessation of bleeding. 
[9] Side effects associated with octreotide therapy are usually mild or transient. These include 
diarrhea, nausea, vomiting, hyperglycemia, inhibition of gallbladder contractility.[10] Vitamin 
B12 deficiency has also been reported. In a prospective study, octreotide treatment was 
discontinued in 5 of 24 patients due to adverse events such as thrombocytopenia, 
choledocholithiasis and biliary sepsis, severe joint pains, severe injection site pain and acute 
blistering skin reaction, in five of twenty-four patients.[7] The simple route of administration and 
lack of major adverse events makes it a valuable potential alternative therapy to endoscopy. [11] 
 
Other medical therapies have been studied for control of bleeding due to AD. An open label 
randomized trial investigated the efficacy of thalidomide for refractory bleeding over four 
months in 55 patients, 52 of whom were found to have AD. Response rate in the thalidomide and 
control groups were 71.4% and 3.7%, respectively. [12] Hormonal therapy with estrogen and 
progesterone has also been tried. One double-blind randomized controlled trial assessed the long 
term efficacy of estrogen-progesterone therapy in 72 cirrhotic patients for recurrent bleeding 
from AD. No significant differences were found between the groups in terms of number of 
bleeding episodes and transfusion requirements over more than one year of follow up. Treatment 
failure occurred in 39% patients in the treatment group compared to 46% patients in the placebo 
group. [13]  
 
Endoscopic treatment of AD has been utilized in the form of heat coagulation or APC. A 
systematic review in 2014 analyzed data from 63 studies with medical or endoscopic treatment 
of bleeding angiodysplasias and GAVE. This review found that the studies evaluating the 
endoscopic modalities have been retrospective with small number of patients, leading to 
insufficient evidence to support efficacy of any single endoscopic therapy.[14] 69 patients 
undergoing endoscopy with APC treatment were followed up for a mean period of 17.3 months 
in a retrospective study. The median number of treatment sessions was 1.49. In 46 patients 
requiring blood transfusion, the mean pre-treatment hemoglobin of 7.3 g/dL increased to 9.3 
g/dL. The median transfusion requirement decreased from 2.5 to 0.1 units of packed red blood 
cells after treatment. Rebleeding was observed in 33.3% patients after a mean period of around 
12 months of follow up. The overall survival without rebleeding was 50% and 42% at 1 and 2 
years respectively. [15]   
 
The lack of pediatric data on the use of octreotide in pediatric patients has limited its use in this 
population. It is not currently FDA approved for management of bleeding due to AD and is used 
as an off-label drug. [11] The patients in this report needed hospitalization due to gastrointestinal 
bleeding secondary to angiodysplasias. The bleeding stopped with stabilization of hemoglobin 
after initiating octreotide and patients did not have recurrence of bleeding. Given the published 
recurrence rate of bleeding and potential impact in these children, octreotide was continued for a 
prolonged period. The main limitations of this study are the small number of patients and the 
challenges associated with determining the dose and duration of the octreotide therapy. These 
patients had a desirable outcome after starting octreotide, although a causative relationship 
cannot be established. Given the limited therapeutic armamentarium and the potentially high 
morbidity of gastrointestinal bleeding in the cardiac population, identification of the potential use 
of octreotide in this setting is important. Larger scale studies are needed to determine the efficacy 
of octreotide in controlling gastrointestinal bleeding due to AD in pediatric patients. 
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Figure 1  
 
 
                                   
 
Upper endoscopy images of angiodysplasia, Patient A 
  
Figure 2- Hemoglobin trend, Patient A 
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Figure 3 
 
 
H&E stain microscopic image of angiodysplasia on biopsy of Terminal Ileum, Patient B 
  
Figure 4- Hemoglobin trend, Patient B 
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